Impact BioMedical (IBO) financial statements
Impact BioMedical reported revenue of $32,000 in fiscal 2025, down 13.8% a year over 3 years.
Net income was -$12M and the operating margin -13381.2%, against -6808.0% in 2022.
The diluted share count fell 55% over the period (buybacks).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Impact BioMedical's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $50,000 | — | — | $32,000 |
| Cost of revenue | — | — | — | $424,000 |
| Gross profit | — | — | — | -$392,000 |
| Research and development | $1M | $2M | $278,000 | $340,000 |
| Selling, general and admin | $325,000 | $315,000 | $718,000 | $873,000 |
| Operating income | -$3M | -$4M | -$29M | -$4M |
| Interest expense | $462,000 | $444,000 | $1M | $793,000 |
| Pre-tax income | -$8M | -$4M | -$25M | -$14M |
| Income tax | -$621,000 | — | $33,000 | -$3M |
| Net income | -$7M | -$4M | -$25M | -$12M |
| EPS (diluted) | -$0.10 | -$0.07 | -$2.30 | -$0.38 |
| Diluted shares | 70M | 60M | 11M | 32M |
| Gross margin | — | — | — | -1225.0% |
| Operating margin | -6808.0% | — | — | -13381.2% |
| Net margin | -14510.0% | — | — | -36993.8% |
Balance sheet
Fiscal years, from Impact BioMedical's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash and short-term investments | $2,000 | $1,000 | $2M | $3,000 |
| Receivables | — | $0 | $201,000 | $5,000 |
| Inventory | — | — | — | $63,000 |
| Total current assets | $122,000 | $332,000 | $2M | $411,000 |
| Property, plant and equipment | $276,000 | $287,000 | $17,000 | — |
| Goodwill | $25M | $25M | $25M | — |
| Total assets | $46M | $45M | $20M | $17M |
| Total current liabilities | $11M | $13M | $10M | $1M |
| Total liabilities | $14M | $16M | $13M | $2M |
| Shareholders' equity | $30M | $25M | $4M | $12M |
| Net debt | -$2,000 | -$1,000 | -$2M | -$3,000 |
Cash flow
Fiscal years, from Impact BioMedical's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -$2M | -$3M | -$3M | -$2M |
| Stock-based compensation | — | — | $19,000 | $13,000 |
| Net borrowing | — | $3M | $1M | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IBO.
Open IBO in InvestinglyQuestions
What was Impact BioMedical's revenue in 2025?
$32,000 in fiscal 2025, from its 10-K filing.
From Impact BioMedical's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.